Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid CancerRazelle Kurzrock, Ravi Salgia, Roger B. Cohen et al.|Journal of Clinical Oncology|2011Cited by 551
The Pharmacogenetics Research Network: From SNP Discovery to Clinical Drug ResponseKathleen M. Giacomini, Issam Zineh, Christopher M. A. Brett et al.|Clinical Pharmacology & Therapeutics|2007Cited by 243